• The effect of infliximab in patients with chronic low back pain and Modic changes (the BackToBasic study): study protocol of a randomized, double blind, placebo-controlled, multicenter trial 

      Gjefsen, Elisabeth; Bråten, Lars Christian Haugli; Goll, Guro Løvik; Wigemyr, Monica; Bolstad, Nils; Valberg, Morten; Schistad, Ellina Iordanova; Marchand, Gunn Hege; Granviken, Fredrik; Selmer, Kaja Kristine; Johanessen, Anne Froholdt; Haugen, Anne Julsrud; Dagestad, Magnhild Hammersland; Vetti, Nils; Bakland, Gunnstein; Lie, Benedicte Alexandra; Haavardsholm, Espen A.; Nilsen, Aksel Thuv; Holmgard, Thor Einar; Kadar, Thomas; Kvien, Tore Kristian; Skouen, Jan Sture; Grøvle, Lars; Brox, Jens Ivar; Espeland, Ansgar; Storheim, Kjersti; Zwart, John-Anker (Peer reviewed; Journal article, 2020)
      Low back pain is common and a significant number of patients experience chronic low back pain. Current treatment options offer small to moderate effects. Patients with vertebral bone marrow lesions visualized as Modic ...
    • Long‐term efficacy and safety of biosimilar infliximab (CT‐P13) after switching from originator infliximab: Open‐label extension of the NOR‐SWITCH trial 

      Goll, Guro Løvik; Jørgensen, Kristin Kaasen; Sexton, Joseph; Olsen, Inge Christoffer; Bolstad, Nils; Haavardsholm, Espen A.; Lundin, Knut Erik Aslaksen; Tveit, Kåre Steinar; Lorentzen, Merete; Berset, Ingrid Prytz; Fevang, Bjørg-Tilde Svanes; Kalstad, Synnøve; Ryggen, Kristin; Warren, David; Klaasen, Rolf; Asak, Øivind Wessel; Baigh, Somyeh; Blomgren, Ingrid; Brenna, Øystein; Bruun, Trude J; Dvergsnes, Katrine; Frigstad, Svein Oskar; Myrnes, Inger; Hatten, Ingvild Helgheim; Huppertz-Hauss, Gert; Henriksen, Magne; Hoie, Sunniva S.; Krogh, Jan Reidar; Midtgard, Irina P.; Mielnik, Pawel; Moum, Bjørn; Noraberg, Geir; Poyan, Armin; Prestegård, Ulf; Rashid, Haroon Ur; Strand, Eldri Kveine; Skjetne, Kristine; Seeberg, Kathrine; Torp, Roald; Ystrøm, Carl Magnus; Vold, Cecilia; Zettel, Camilla C.; Waksvik, Kenneth; Gulbrandsen, Bjørn; Hagfors, Jon; Mørk, Cato; Jahnsen, Jørgen; Kvien, Tore Kristian (Journal article; Peer reviewed, 2019)
      Background and objectives The 52‐week, randomized, double‐blind, noninferiority, government‐funded NOR‐SWITCH trial demonstrated that switching from infliximab originator to less expensive biosimilar CT‐P13 was not ...